Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Stratification of responders towards eculizumab using a structural epitope mapping strategy.

Scientific reports - 11 Aug 2016

Volk Anna-Luisa, Hu Francis Jingxin, Berglund Magnus M, Nordling Erik, Strömberg Patrik, Uhlen Mathias, Rockberg Johan

Abstract excerpt

The complement component 5 (C5)-binding antibody eculizumab is used to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS). As recently reported there is a need for a precise classification of eculizumab responsive patients to allow for a safe and cost-effective treatment. To allow for such stratification, knowledge of the precise binding site of the drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CHO Cells
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Binding Sites

Share to Complement C5

Share to Cricetulus

Share to Crystallography, X-Ray

Share to Epitope Mapping

Share to Protein Domains

Source

Open in PubMed Open full text

Identifiers

PMID: 27509843
DOI: 10.1038/srep31365
PMCID: PMC4980765

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Stratification of responders towards eculizumab using a structural epitope mapping strategy.PMID 27509843Read ↗

Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.Semantic proximity Read ↗

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodiesSemantic proximity Read ↗

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodiesSemantic proximity Read ↗

Rational Engineering of a Minimized Immune Inhibitor with Unique Triple-Targeting PropertiesSemantic proximity Read ↗

Atypical HUS: time to take stock of current guidelines and outcome measures?Semantic proximity Read ↗

Genetic Variants in C5 and Poor Response to EculizumabSemantic proximity Read ↗

Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5.Semantic proximity Read ↗

The common equine class I molecule Eqca-1*00101 (ELA-A3.1) is characterized by narrow peptide binding and T cell epitope repertoires.Semantic proximity Read ↗

Multifaceted Activities of Seven Nanobodies against Complement C4bSemantic proximity Read ↗

Novel unconventional binding site in the variable region of immunoglobulins.Semantic proximity Read ↗

The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studiesSemantic proximity Read ↗

Computational design of N‐linked glycans for high throughput epitope profilingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.